knowledge -WSS

knowledge

author：entertainment 2025-09-29 01:45:28 - browse：2

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Americans' trust in science, scientist continues decline: Report

focus

WSS

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

FDA approves world's first CRISPR

After sickle

Startup Neumora takes a novel depression drug to Phase 3

At Orexo, a ‘turning point’ for everything but digital health

CMS should re

explore

knowledge

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA approves RSV monoclonal antibody for infants, toddlers

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Teach medical students about patients with intellectual disabilities

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Custom gene therapy hints at new path for rare disease treatments

In age of alternative facts, a scholarly course on calling out crap

How dance can help nurses traumatized by Covid

DIEP, the 'gold standard' of breast reconstruction, is under threat

Pfizer plans to depart BIO

focus

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Americans' trust in science, scientist continues decline: Report

AI can’t replace a physician’s gut feeling

How dance can help nurses traumatized by Covid

Google and Epic fight stronger regulation of AI in health care

FDA approves world's first CRISPR

hotspot

focus

explore

leisure time